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Abstract
A cornerstone of autologous cell therapy for Duchenne muscular dystrophy is the engineering of suitable cells 
to express dystrophin in a stable fashion upon differentiation to muscle fibers. Most viral transduction methods are 
typically restricted to the expression of truncated recombinant dystrophin derivatives and by the risk of insertional 
mutagenesis, while non-viral vectors often suffer from inefficient transfer, expression and/or silencing. Here we 
addressed such limitations by using plasmid vectors containing nuclear matrix attachment regions (MAR). Using in 
vitro transfection and intra muscular transplantation in nude and immunosuppressed mdx mice, we show that clones 
of mesoangioblast skeletal muscle progenitors can be generated to mediate stable expression from MAR-containing 
vectors, while maintaining their ability to differentiate in vitro and in vivo and to express dystrophin after transplantation 
in dystrophic mouse muscles. We conclude that the incorporation of MARs into plasmid vectors may improve non-viral 
plasmid-based cell therapy feasibility.
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Introduction
Duchenne muscular dystrophy is an X-linked progressive muscular 
wasting disease that affects skeletal and cardiac muscles, and for which 
there is currently no cure. It is caused by mutations in the dystrophin 
gene, resulting in the lack or reduction of the protein. This deficit leads 
to a disruption of the dystroglycan complex and destabilization of the 
sarcolemma, resulting in progressive muscle wasting [1]. Promising 
experimental approaches that aim to restore the dystrophin complex at 
the sarcolemmal membrane include i) exon skipping by pharmacological 
strategies, ii) systemic gene therapy and iii) cell therapy [2,3]. Gene 
therapy approaches aim to engineer vectors that efficiently transduce 
myofibers with a dystrophin expression cassette, whereas cell therapy 
approaches aim to deliver the dystrophin transgene to the myofiber 
by stem/progenitor cells, while preferably replenishing the satellite 
cell pool with genetically corrected or complemented autologous 
cells. In this study, we assessed a novel approach to express full-length 
dystrophin in a cell therapy setting.
Besides myoblasts, multiple myogenic stem/progenitor cells were 
described for potential use in cell therapy. Unlike myoblasts that 
require high-density injection and are limited to superficial muscles [4], 
mesoangioblasts can cross the blood vessel wall and home into damaged 
muscle after intra-arterial delivery [5], thus providing an approach 
towards systemic cell therapy [6-9]. Mesoangioblasts were isolated 
from mice, dogs and humans, and they maintain their differentiation 
potential upon in vitro culture. Although aneuploidy and transformation 
may be observed upon prolonged culture of murine cells, human and 
canine mesoangioblasts maintained a normal karyotype and did not 
escape eventual senescence in long-term cultures [10,11].
The therapeutic potential of wild-type mesoangioblasts 
injected intra-arterially was shown in α-sarcoglycan null mice 
and dystrophic dogs, leading to dramatic improvement of muscle 
morphology and function [9,10,12]. In contrast, the therapeutic 
efficacy of transplantations with viral vector-transduced dystrophic 
mesoangioblasts was modest. This may result in part from the 
transcriptional silencing of the transgene by epigenetic effects [13]. 
In addition, limitations of typical viral vector cargo size necessitated 
the development of shorter, Becker-like dystrophins, which may have 
reduced therapeutic effects [14]. Despite significant advances in viral 
vector engineering, safety concerns remain regarding genotoxic effects 
and potential malignant cell transformation, because of the tropism of 
some viral vectors for cellular genes [15]. Use of non-viral vectors or 
gene correction may be promising alternative approaches. However, 
their efficiency remains generally low, and gene correction is also 
limited by the breadth of mutations that affect dystrophic patients [16]. 
Therefore, expression of truncated dystrophin derivatives from viral 
vectors is still mostly used in experimental cell therapy approaches.
Strategies that allow the introduction of a functional copy of the full-
length dystrophin coding sequence into autologous cells might thus be 
beneficial. Current efforts are thus increasingly focused on the isolation 
of single clones and on the characterization of the genomic integration 
locus to reduce the risk of adverse effects. Here, we investigated a 
novel non-viral transgene introduction approach as an alternative to 
viral vector transduction, assessing whether the stable transfection of 
nuclear matrix attachment regions (MAR)-containing plasmids may 
allow the engineering of primary muscle precursor cells. A recent 
genome-mining effort yielded potent human MARs (hMARs) that 
enhance and stabilize transgene expression in cultured cells as well as in 
murine muscles [17]. hMAR elements were shown to promote plasmid 
integration in the host cell genome by homologous recombination-
related mechanisms, to increase transgene transcription and to oppose 
epigenetic silencing effects in cultured rodent and human cells [17-21].
In this study we evaluated plasmid vectors containing distinct MAR 
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elements to promote transgene expression in mesoangioblasts, in an 
attempt to improve non-viral engineering of muscle progenitors for 
cell therapy. We show that MARs increase stable transfection efficiency 
up to 10-fold. Clones generated with MAR-containing vectors retained 
their ability to differentiate in vitro and in vivo while sustaining 
transgene expression. This indicates that transfection-based cell therapy 
approaches may be improved with MAR element-containing non-viral 
vectors. 
Materials and Methods
Cell culture
MDX mesoangioblasts cultures were established and cultured in 
Dulbecco’s modified eagle medium (DMEM, Gibco) containing 20% 
FBS as described previously, and provided by G Cossu, Milan [22]. 
C2C12 mouse myoblasts were maintained in DMEM (Gibco) plus 10% 
FBS. All culturing was done in a humidified 37°C/5% CO2 incubator. 
Differentiation was induced by the co-culture of C2C12 cells and 
mesoangioblasts at a 1:4 ratio in DMEM 20% for 24h, after which the 
culture medium was changed to DMEM plus 2% horse serum. Myotube 
formation was confirmed by immunofluorescence for α-actinin using 
a mouse polyclonal antibody (Sigma). eGFP expression levels of 
differentiated and undifferentiated mesoangioblasts were recorded by 
fluorescence microscopy.
DNA constructs and transfection
The construction of MAR-containing eGFP expression vectors was 
as previously described [17]. pMDA (full length mouse dystrophin 
cDNA driven by the muscle creatine kinase promoter) was kindly 
provided by JS Chamberlain [23]. Plasmids were amplified in DH5α 
bacteria and purified using a plasmid maxiprep kit (Genomed). 
Transfections were done with Lipofectamine 2000 (Invitrogen), 
Fugene 6 (Roche), Fugene HD (Roche), while electroporations were 
performed using the Nucleofector (Amaxa) or the Neon electroporator 
(Invitrogen) following the manufacturers’ instructions. For equimolar 
transfections of various eGFP-expressing constructs, pUC18 was added 
to maintain an equal amount of total DNA. Cells were plated 27 h 
before transfection to allow an appropriate timing of the transfection 
with the cell cycle, as adapted from [17]. At time of transfection cell 
confluency was 80%, and 4.5 µl of Fugene HD was added together with 
2 µg of plasmid DNA. For stable clone isolation, the cells were placed 
after 48 h post transfection in DMEM supplemented with 20% FBS 
and 2.5 µl/ml puromycin dihydrochloride (Sigma). After 20-30 days, 
eGFP expressing clones were isolated by mechanical dislodging of the 
colony with a sterile pipet tip. Transfection efficacy was measured by 
fluorescence acquisition for eGFP using a fluorescence-activated cell 
sorter (FACSCalibur, BD biosciences). 100,000 events were counted 
per given cell population. Statistical analyses were performed with the 
Student’s t test. The described lentivirally transduced mesoangioblast 
population was generated as described previously [6,9].
Plasmid rescue for genomic integration locus DNA 
sequencing
We extracted total genomic DNA from cells with the Blood and 
Tissue kit (QIAGEN), following the manufacturer’s instructions. After 
digestion of 2 µg of genomic DNA with a unique restriction site cutter, 
BamHI (NEB), we took 1/10 of digested DNA and ligated with 15 µl 
T4DNA ligase (NEB) in 500 µl at 16°C over-night. The ligation was 
dialysed against water, precipitated and resuspended in 4 µl, of which 
1 µl was used to transform 20 µl of electrocompetent DH10B cells 
(Invitrogen). 
In vivo transplantation assay
5 x 105 cells were suspended in 30 µl phosphate buffered saline 
(PBS) and injected intramuscularly in the Tibialis anterior of 5 
wk old CD-1 nude (Charles river), C57Bl6 or mdx5cv mice using a 
29G ‘Myjector’ syringe (Terumo), while the contralateral muscle 
was injected with PBS alone. 3 mice were transplanted for each cell 
clone. During the procedures, the mice were anaesthetized by intra-
peritoneal injection with xylazine/ketamine. Mice were sacrificed by 
cervical dislocation at day 9, day 40 or 3 months post injection, and 
muscles were collected and frozen in liquid nitrogen cooled isopentane 
(Sigma). All precautions were taken to reduce animal suffering, and the 
procedures were approved by the Service de la consommation et des 
Affaires vétérinaires of the Canton of Vaud (Lausanne, Switzerland). 
Immunofluorescence for eGFP was performed using a rabbit polyclonal 
antibody (Invitrogen) on paraformaldehyde 4% fixed sections. 
Dystrophin staining was performed on non-fixed 10 µm TA sections 
using mouse monoclonal antibodies NCL dys1 and NCL dys2 from 
Novocastra (Leica).
Fluorescence in situ hybridization
Mesangioblast clones were exposed for 2 hours to colcemid 
(Invitrogen) to block cell division in metaphase. After harvesting, 
cells were exposed to a hypotonic shock with 37.5 mM KCl for 20 
minutes, fixed with 25% acetic acid and 75% methanol and spread 
onto superfrost microscope slides. Hybridization probes were prepared 
using a nick translation DNA labeling system (Enzo Life Sciences) and 
Orange 552 dUTP (Enzo Life Sciences) according to the manufacturer’s 
instructions. The probe targeting eGFP was generated from the eGFP 
expressing vector devoid of MAR whereas the dystrophin probe was 
derived from the pMDA vector. Precipitated probes were resuspended 
in hybridization buffer (2x SSC, 50% formamide, 10% Dextran Sulfate), 
denaturated for 10 min at 75°C, cooled down on ice and finally pre-
warmed at 37°C. Before applying the probes, slides were washed in PBS, 
denaturated in denaturation buffer (2x SSC, 70% formamide at 75°C), 
dehydrated through ethanol series performed at room temperature 
(70%, 85%, 100%) and air-dried. Hybridization occurred overnight at 
37°C. Slides were first washed for 90 seconds with 0.4x SSC and 0.3% 
NP-40 at 72°C followed by a 1 minute wash in 2x SSC and 0.1% NP-40 
at room temperature. Metaphases were counterstained with Vectashield 
Mounting Medium with DAPI (Vector Labs) and observed using a 
100X oil immersion objective on an Axio Vert Inverted microscope 
(Carl Zeiss).
Imaging
Microphotographs of eGFP autofluorescence, DAPI and secondary 
antibodies conjugated with Alexa fluor 546 were made with an Observer 
A.1 equipped with an Axiocam (Zeiss) using the Axiovision software. 
Results
Optimizing transfection of primary murine mesoangioblasts
A panel of human and animal MAR elements was tested for their 
effect on the establishment of stable cell clones and for transgene 
expression level and stability using murine mesoangioblasts (Table 1). 
The MAR elements were inserted upstream of the SV40 promoter and of 
the eGFP coding sequence. As primary progenitor cells are often difficult 
to transfect, we first tested several transfection reagents and assessed 
the transient eGFP fluorescence levels in primary mesoangioblasts that 
were obtained from the commonly used mdx-5Cv mouse model for 
Duchenne muscular dystrophy. Transient transfection with Fugene HD 
was most efficient, with 14.5% and 9.3% of eGFP positive cells with the 
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MAR-devoid and hMAR X-29-containing plasmids, respectively, while 
other reagents yielded lower transfection efficacies, as measured by 
FACS for GFP autofluorescence 48 h after transfection. As transfections 
were carried out with equimolar amounts of plasmid, the lower eGFP 
obtained from the hMAR X-29 MAR construct likely resulted from 
the larger plasmid size and thereby reduced transfection efficacy. 
Electroporation also proved to be a very efficient transient transfection 
method, yielding up to 20% eGFP expressing cells after 48 h (Figure 1).
Transfection of primary murine mesoangioblasts by various 
approaches
Transfection was done according to manufacturers instructions 
using optimized amounts of DNA. The percentage of eGFP positive cells 
was recorded 48h after transfection by FACS cytofluorometry (A) or 
fluorescence microscopy (representative fields shown, panel B). Scale bars 
indicate 200 µm. FACS profiles of eGFP expression obtained from the 
hMAR X-29-containing vector of from a control construct devoid of any 
insert (no MAR), as determined 48 h after transfection with lipofectamine 
2000 (C) or Fugene HD (D). Cells were transfected with equimolar 
amounts of either the no MAR eGFP or the hMAR X-29 eGFP plasmid.
Effect of MARs on stable transfection efficacy of primary 
murine mesoangioblasts
The MAR-eGFP or control vectors were then co-transfected with 
a plasmid bearing the puromycin-resistance gene and puromycin was 
added to the transfected cell pools for up to 30 days. This selection 
period allowed for the formation of colonies of antibiotic resistant cells 
of sufficient size to be picked manually and individually. Despite the 
low initial number of eGFP positive cells at 48 h, the vector containing 
hMAR X-29 showed a statistically significant 10-fold increase of stable 
eGFP-expressing clones as compared to the MAR devoid construct, 
and up to a ~ 60x increase when compared to the vector whose MAR 
element was substituted by a genomic fragment of comparable size 
but without MAR activity (Figure 2A). Overall, 1.8 x 105 transfected 
cells yielded on average 17 eGFP-expressing clones when using hMAR 
X-29. While electroporation yielded the highest efficacy of transient 
eGFP expression, the subsequent selection of cells mediating sustained 
transgene expression under antibiotic selection yielded no stable clones 
from the two electroporation devices tested (Figure 1A). Therefore, 
subsequent transfections performed to generate stable clones relied on 
the Fugene HD reagent.
With hMAR X-29, 82 ± 17 % of the obtained clones expressed 
eGFP, which was significantly higher than the 26 ± 14 % of expressing 
clones obtained with the MAR-devoid construct (p<0.05, student’s 
t-test), and the 11 ± 19% recovered for the construct containing 
a non-MAR control genomic fragment (p<0.01; See S1 Table for a 
summary of all clones). hMAR 1-68 also significantly increased stable 
transfection efficacy by ~ 6x as compared to the no MAR control 
(p<0.05). Other human MARs, namely hMAR 1-6 and 1-42 also 
showed a positive trend for stable transfection efficacy. The chicken 
lysozyme (cLys) MAR was the only tested element that did not show a 
detectable effect (Figure 2A).
MAR name Species of origin MAR size (bp)
Control genomic DNA Human Chr. 1 2275
hMAR 1-6 Human Chr. 1 4618
hMAR 1-42 Human Chr. 1 4660
hMAR 1-68 Human Chr. 1 3643
hMAR X-29 Human Chr. X 3343
cLys MAR Chicken Chr. 1 2827
Mouse MAR S4 Mouse Chr. 1 5457
These MAR elements were previously described in references [6,9].
Table 1: Overview of MAR elements used in this study. 
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Figure 1: Transfection of primary murine mesoangioblasts by various approaches. Transfection was done according to manufacturer’s instructions using optimized 
amounts of DNA. The percentage of eGFP positive cells was recorded 48 h after transfection by FACS cytofluorometry (A) or fluorescence microscopy (representative 
fields shown, panel B). Scale bars indicate 200 µm. FACS profiles of eGFP expression obtained from the hMAR X-29-containing vector of from a control construct devoid 
of any insert (no MAR), as determined 48 h after transfection with lipofectamine 2000 (C) or Fugene HD (D) Cells were transfected with equimolar amounts of either the 
no MAR eGFP or the hMAR X-29 eGFP plasmid.
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Overall, the maximum level of eGFP fluorescence of individual 
colonies was higher in presence of hMAR X-29 than for clones generated 
without a MAR (Figure 2B and Table S1). Analysis of the mean 
fluorescence of the 4 highest expressing clones generated with hMAR 
X-29 or without a MAR yielded 39 and 10.5 relative fluorescence units 
(RFU), respectively. Clones displaying the highest eGFP fluorescence 
were isolated from the transfections performed with or without the 
hMAR X-29, and they were subsequently expanded without antibiotic 
selection pressure. eGFP expression was rapidly lost in the isolated 
clone generated using the vector containing the control genomic DNA, 
whereas it was stable for the hMAR X-29-containing clone (Figure 2C 
and 2D). While selection allowed the maintenance of eGFP expression 
in the control MAR-devoid cells after 30 days of culture, the selection 
pressure had no noticeable effect on transgene expression in the hMAR 
X-29-containing clone, indicating a lack of detectable silencing over 
this time-period in presence of the MAR.
In vitro and in vivo differentiation of clonal primary murine 
mesoangioblasts
We next tested whether transfected mesoangioblasts retained 
their myogenic differentiation potential. Thus, we co-cultured the 
mesoangioblasts with the C2C12 murine myoblast cell line under 
myogenic differentiation conditions, to induce the in vitro co-
differentiation and fusion of these cells into myotubes. Most clones 
generated with the MAR yielded eGFP-expressing myotubes in such 
assay, indicating that the mdx mesoangioblast cells had maintained their 
ability to fuse with differentiating myotubes, and that differentiation was 
not accompanied by the silencing of the transgene (S1 Table and Figure 
S1). In contrast, eGFP expression was low prior to differentiation in the 
cells generated without the MAR, and it became nearly undetectable 
after myotube differentiation (Figure S2 and data not shown).
Overall, we were unable to obtain a clone devoid of the MAR that 
would express sufficient eGFP levels for detection in subsequent in vivo 
differentiation assays with this approach. Thus, we adapted an iterative 
transfection procedure phased on the cell division cycle, as described 
previously for CHO cells, in which the cells were transfected a second 
time 27 h after the first transfection [19]. One of the resulting clones 
had an expression level close to those of hMAR X-29-containing clones 
(Figure 3A and Table S1).
When comparing the eGFP expression levels of stably transfected 
clones to a lentiviral vector-transduced polyclonal population by 
cytofluorometry, the maximum eGFP fluorescence levels were quite 
similar between the hMAR-containing clone and the transduced 
population (Figure 3A).
When the clone transfected twice with the MAR-devoid construct 
was assessed in the differentiation assay, eGFP expression could be 
detected. However expression was low in comparison to that elicited 
by the hMAR-containing clone, indicating an expression stabilizing 
effect from the hMAR (Figure 3B). Fusion of mesoangioblasts 
generated with the hMAR allowed significant levels of transgene 
expression in myotubes, despite the fact the latter are formed by an 
excess of non-expressing C2C12 cells. Proper myogenic differentiation 
of the clonal mesoangioblast populations was confirmed by α-actinin 
immunofluorescent staining, indicating that the fusion of transfected 
mesoangioblasts had not impaired myotube formation. The 
transfection and selection protocol had virtually no negative effect on 
the differentiation potential of the mesoangioblasts, as 29 out of 30 
tested eGFP-expressing clones gave rise to eGFP-positive myotubes 
(Table S1).
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Figure 2: Effect of MARs on mesoangioblast stable transfection efficacy.
(A) Mesoangioblasts were transfected with equimolar amounts of eGFP plasmid with or without a MAR insert, as indicated, together with the pSVpuro antibiotic 
resistance plasmid, and selection with 2.5 µg/ml of puromycin was initiated 48 h later. Resistant eGFP positive colonies were quantified after 30 days of selection. 
Statistical significance was determined from at least three independent experiments by unpaired student’s t-test (*: p<0.05, **: p<0.01). (B) Primary colony morphology of 
clones without and with the MAR (clones noMAR 2.3Kb.A and hMAR X-29.J, respectively, as described in the supplementary Table S1). hMAR X29.J has an increased 
RFU of 910% as compared to the noMAR 2.3Kb.A control. These clones generated without (C) or with (D) the MAR displaying the highest expression were picked 
after 20-30 days of antibiotic selection, and they were further cultured with or without antibiotic selection. eGFP expression levels were assessed by cytofluorometry at 
different time-points, where day 0 refers to the day of antibiotic removal. 
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Transgene integration site determination in transfected 
stable mesoangioblast clones
We next wished to determine the number of transgene integration 
sites by fluorescent in situ hybridization (FISH). Aneuploidy was found 
in metaphase spreads of parental cells and of the transfected clones, 
as expected from the long-term culture of the mouse mesoangioblasts. 
Similar chromosome numbers were found in the clonal populations 
and in the parental cells prior to transfection, indicating that the 
transfection procedure did not cause chromosomal abnormalities 
per se (Figure S2A). A single integration site was found in all tested 
clones, although the genomic integration locus varied from clone to 
clone (Figure 4). While a unique integration locus is advantageous in 
terms of safety when compared to vectors yielding multiple integration 
sites like retroviral vectors, we nevertheless wished to determine if the 
genomic integration site may be identified in individual clones, so as to 
assess the potential insertional mutagenesis of cellular genes. Thus, we 
next attempted to characterize the genomic integration site of clones 
generated with MAR-eGFP plasmids.
Genome-integrated vectors were released by digesting total 
genomic DNA with a restriction enzyme that cleaves the plasmid once 
and fragments were circularized by ligation. Plasmids were rescued by 
bacterial transformation and sequence determination of the genomic 
flanking DNA region of the plasmid rescued from the hX29.J clone 
showed transgene integration into an intronic region of solute carrier 
family 12 member 8 gene, on chromosome 16. As this and other related 
genes have not been linked to oncogenesis, we predicted that the 
hX29.J clone would not give rise to tumors in vivo. Although we were 
unsuccessful in determining the transgene integration sites for other 
clones due to the low intrinsic success rate of the protocol, no safety 
issues related to mutagenesis arose as no tumorigenesis was observed 
during subsequent mouse experiments.
Following the validation of the eGFP-expressing clones for in vitro 
differentiation and for the lack of potentially oncogenic mutagenic 
event elicited by plasmid genomic integration, we investigated the 
in vivo differentiation potential of the hMAR X-29.J and noMAR.B 
clones. 5 x 105 cells were injected intra-muscularly into the Tibialis 
anterior (TA) of 5-week old CD-1 nude mice. Cells from the lentiviral 
vector-transduced population were similarly injected as a control. Both 
transfected clones differentiated into eGFP-positive myofibers after 
transplantation (Figure 3C). In agreement with in vitro differentiation 
results, the hMAR X-29.J transplanted TA resulted in fibers displaying 
higher eGFP levels than the muscle transplanted with the MAR-devoid 
clone (Figure 3D). 
Transfection and differentiation of primary murine 
mesoangioblasts with dystrophin
We then proceeded to generate dystrophin-expressing clones from 
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Figure 3: In vitro and in vivo differentiation of clonal eGFP-expressing mesoangioblasts.
(A) Comparison of the eGFP expression levels from clones obtained from an iterative transfection of transfected clones of a MAR-devoid eGFP expression vector 
(clone noMAR.B), from a single transfection of the hMAR X-29-containing vector (clone X-29.J), or from a polyclonal population of mesoangioblasts transduced with 
an eGFP-expressing lentiviral vector. The cytofluorometric profiles for eGFP fluorescence were monitored for each population. (B) Differentiation of the noMAR.B 
and hMAR X-29.J cell clones after a co-culture with C2C12 cells for 7 days in differentiation medium. eGFP fluorescence is shown in green, while the α-actinin 
immunofluorescence performed to determine myogenic differentiation and DAPI nuclear staining are displayed in red or blue, respectively. Scale bars indicate 50 
µm. (C-E) In vivo transplantation of eGFP-expressing mesoangioblasts clones with hMAR X-29 (clone X29.J, panel C) or without a MAR (noMAR.B, panel D), and of 
a lentiviral vector-transduced mesoangioblast polyclonal population without a MAR. A single intramuscular injection with 5 x 105 cells was done in the TA of 5 wk old 
CD-1 nude mice, and muscles were isolated for immunostaining at day 9 after injection. Brightness and contrast were increased for better visibility of the muscle fibers 
delineation for the red channel (WGA) of the enlargement panels (C, D and E).
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the mdx mesoangioblasts by co-transfecting the puromycin selection 
gene with the full-length murine dystrophin cDNA placed under the 
control of the muscle creatine kinase promoter. Various MAR-eGFP 
expression plasmids were co-transfected at equimolar amounts to 
supplement the dystrophin sequence with the MAR elements in trans, 
as previous evidence indicated that distinct plasmids co-integrate at the 
same genomic locus upon co-transfection [17]. No clone was obtained 
without a MAR, despite good initial transfection efficacies, and we 
did not obtain eGFP-expressing clones with hMAR X-29 either. This 
could be attributed to the fact that in presence of hMAR X-29, the 
muscle specific MCK promoter displayed a leaky expression in non-
differentiated cells (Figure S3), which leads to cellular toxicity effects 
due to ectopic dystrophin expression. However, relatively less potent 
MARs such as the cLys and h1-6 MAR generated 1 and 3 clones, 
respectively. Transfection with a mouse MAR termed S4 yielded three 
additional clones. Consistently with the results from the earlier eGFP-
expressing clones, all dystrophin vector-transfected clones yielded a 
single transgene integration locus (Figure S2B and S2C). In addition, 
all these clones were found to co-differentiate with C2C12 cells to yield 
eGFP-expressing myotubes in vitro (Figure 5A-5C). These five clones 
were transplanted in the TA muscles of 5-week old mdx mice, which 
were immunosuppressed with FK506 until sacrifice to prevent rejection 
A B
C D
Figure 4: Clones derived from plasmid transfection have single genomic integration sites.
Representative FISH images of clones used for in vivo transplantation studies. Arrows indicate the transfected plasmid integration sites. Inlays are enlargements of 
transgene-bearing chromosomes. (A) eGFP clone X29.J. (B) eGFP clone noMAR.B. (C) eGFP clone S4.B. (D) eGFP clone 1-6.E. 
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Figure 5: Differentiation and in vivo dystrophin expression from transfected mesoangioblast stable cell clones.
In vitro differentiation assays were performed on all selected clones, and the eGFP expression, α-actinin staining and an overlay are shown at day 7 after a co-culture 
with C2C12 cells in the co-differentiation assay conditions. A representative clone for each of the expression construct is shown, namely clone h1-6dys.E (panel A), 
cLysdys.D (panel B) and mS4dys.C (panel C). Scale bars represent 100 µm. (D) Dystrophin staining on cross-section of TA from a 5 wk old C57Bl6 mouse (positive 
control, panel D) and cross-section of a TA from a 5 wk old mdx mouse 1 month after a single intra-muscular injection with 5 x 105 cells of the S4dys.D clone (panel E). 
Mdx mice were immunosuppressed by daily injections of FK506 before sacrifice, and dystrophin-positive fibers were counted in distal and proximal transversal sections 
of each TA muscle. The scale bar represents 50 µm. (F) Dystrophin positive fibers were counted for the negative control (n=6) and after transplantation of cells from the 
h1-6dys.E (n=12), mS4dys.C (n=6), mS4dys.D (n=12), mS4dys.A (n=4), or cLysdys.D (n=10) clones.
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of the allogeneic cells. The number of dystrophin positive fibers was 
then counted 1 month after transplantation in immunostaining studies 
of proximal and distal cross-sections of the TA of all mice. Overall, the 
dystrophin expression levels of injected mdx TA muscles were lower 
than those of wild-type myofibers, but clusters of dystrophin expressing 
fibers could be observed in muscles transplanted with clones S4dys.D 
and 1-6dys.E along with centrally located nuclei indicative of muscle 
fiber regeneration (Figure 5D and 5E). No such cluster of dystrophin-
expressing cells was detected from the transplantation of the other 
three clones or from the muscles of non-transplanted animals (Figure 
5F). Overall, we concluded that some of the transfected clones were 
capable of dystrophin expression after transplantation into the muscle 
of dystrophic mdx mice.
Discussion
Non-viral cell-based therapy has often been limited by gene 
transfer and maintenance, and thus by the lack of cell populations 
mediating stable and consistent expression. Here we showed that stable 
clones could be obtained from the transfection of adult stem cells 
propagated in vitro. This involved the development of methods allowing 
antibiotic selection, the mechanical isolation of single clones, and 
the subsequent expansion in tissue culture in conditions that prevent 
anoikis, an often-noted problem when cultivating isolated primary 
cells. Although mesoangioblasts significantly slowed cell cycling 
when cultured at low density, and a minority of cells showed signs of 
spontaneous differentiation, i.e. a flattened morphology of multiple 
nucleated syncytia, most cells did not exit the cell cycle and expanded 
to form clonal populations expressing the transgene at homogeneous 
levels. Conversely, another limitation of muscle progenitor cells is 
a loss of differentiation potential resulting from contact inhibition, 
when allowing the stable clones to form colonies. However, clones 
grown according to this protocol were consistently able to form 
eGFP-expressing myotubes in vitro, and the inclusion of MARs in the 
expression vector had no negative effect on differentiation.
We showed that several MAR elements of human origin enhanced 
stable transfection efficiency significantly. This effect of MARs cannot 
be related to a simple increase of the transfer of the DNA, as transient 
transfection of MAR bearing plasmids consistently yielded fewer 
fluorescent cells than ones devoid of MAR, even when transfecting 
equimolar amounts of plasmid. Thus, the effect of the MARs is rather to 
increase transgene genomic integration, as required to establish clones 
displaying stable transgene propagation and expression upon cell 
division. This effect of the MARs can be readily explained by the recent 
finding that MARs promote transgene genomic integration in cell lines 
by a homologous recombination-related mechanism [19]. A similar 
increase of the genomic integration of MAR-containing plasmids has 
also been observed in vivo upon plasmid electroporation in murine 
muscles [24]. Thus a more frequent establishment of mesoangioblasts 
cell clones is well explained by the fact that primary cells are known 
to have limiting recombination activity when compared to established 
cell lines [24], and that MAR would thus be required to increase 
integration by such a recombination mechanism. In this respect, it will 
be interesting to characterize transgene integration sequences at a large 
scale, to determine if MARs may promote more frequent occurrence of 
integration at specific types of genomic loci or of chromatin structure. 
Nonetheless, and despite the higher frequency, clone establishment 
remained relatively rare events, yielding up to 10-20 clones per 105 
cells for the most efficient MAR-containing vectors. Therefore, isolated 
primary mesoangioblast populations would have to be expanded 
to close to a million cells in a clinical setting to yield 10-100 clones 
that could be stored and characterized before transplantation. Given 
the genomic stability of human mesoangioblasts and the maintenance 
of their differentiation potential upon culturing in vitro, this might 
be a feasible goal provided that senescence may be avoided during 
culture. This might be achieved for instance by the currently developed 
reversible immortalization of these human cells [25].
In addition to the effect on transgene integration, the human 
MARs were found to have a positive effect on transgene expression 
levels and stability, the most potent in this respect being hMAR X-29. 
In presence of hMARs, clones that expressed eGFP in mononucleated 
mesoangioblasts were in most cases found to maintain eGFP expression 
after differentiation, even in the absence of antibiotic selection pressure. 
Although a clone could be isolated form a MAR-devoid plasmid with 
a comparable expression level as those obtained from mesoangioblasts 
transfected with a MAR, such clones usually had lower expression or 
lost any detectable eGFP fluorescence upon differentiation to myotubes. 
This likely results from the known adoption of less permissive chromatin 
structures such as heterochomatin over large portions of the genome 
upon the differentiation of stem cells [26]. The ability of MARs to 
maintain a transcriptionally permissive chromatin structure, even when 
the chromatin structure is restricted upon myogenic differentiation, 
may thus explain their favorable effect on transgene expression upon 
myotube formation. In addition to the favorable effect of MARs on 
transgene expression, all clones had a single genomic integration site 
as is often the case for transfected cell lines, and this integration site 
can be mapped to increase the safety of potential transfection-based 
clinical protocols. This feature may be advantageous in terms of safety 
when compared to viral or transposable vectors that often integrate at 
multiple and variable number of loci.
Results from in vivo transplantation experiments indicated that 
transfected mesoangioblast clones may lead to eGFP positive myofibers 
upon intramuscular injection as early as 9 days after administration. 
In accordance with their in vitro differentiation properties, the hMAR-
containing clone yielded clearly detectable eGFP expression in vivo, 
whereas the clone without a MAR displayed low eGFP levels. Based 
on these findings we concluded that human MARs like X-29 could 
fulfill some of the requirements of autologous muscle cell therapy. 
While we were able to obtain stable mesoangioblast clones that were 
co-transfected with a plasmid encoding full-length dystrophin driven 
by the muscle creatine kinase (MCK) promoter and some of the 
MAR-bearing eGFP plasmids, transfections with the most potent 
hMAR X-29-containing plasmid consistently yielded no clones. The 
rationale for using a muscle-specific promoter to express dystrophin 
stems from previous observations that the build-up of dystrophin 
protein expression in undifferentiated mesoangioblasts leads to toxicity 
effects, possibly because of the lack of concomitant expression of other 
components of the glycoprotein complex that dystrophin interacts with 
[27,28]. Thus, a likely explanation for the lack of stable clones expressing 
dystrophin in presence of the most potent hMAR X-29 is that the co-
integration of the MAR and the dystrophin construct caused leakiness 
of the MCK promoter, and ectopic expression of dystrophin prior to 
differentiation. This interpretation is indeed supported by data showing 
GFP expression from the MCK promoter in presence of hMAR X-29 
in undifferentiated mesoangioblast cells, which indicated an increased 
leakiness of the muscle promoter in presence of the most potent MAR.
Nevertheless, dystrophin cDNA-containing clones were obtained 
using other MAR elements like the mouse S4, the human 1-6 and the 
chicken lysozyme MAR, and clones obtained with these elements were 
capable of differentiating in vitro and in vivo. Dystrophin expressing 
fibers were found from the injection of the clonal mesoangioblasts. A 
minority of the fibers had dystrophin expression, as expected from the 
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previously reported relatively lower efficacy of a single intramuscular 
injection relative to several consecutive injections (ref. [25] and 
unpublished data from G.C. and collaborators), and also because 
potentiating protocols like the transduction with MyoD vectors or pre-
injection exposure to growth factors were not used [8]. Nevertheless, 
our observations provide a first description of full-length dystrophin 
expression from the stable plasmid transfection of muscle precursor 
cells, followed by their incorporation in muscle fibers in vivo. It thereby 
facilitates a new strategy to pursue a possible treatment of muscular 
dystrophies using genetically-corrected cells.
Overall, the presented approach may be limited to the cells that 
maintain a normal genomic structure and differentiation potential 
when cultured in vitro, and to cloning procedures that allow the 
selection of transgene expressing cells. Overall, we propose that the 
ability to characterize the genomic structure of clonal populations after 
limited expansion may decrease the likelihood of adverse effects and 
may thus open a feasible path towards cell-based therapies involving 
gene transfer.
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